Consumers who purchased generic prescription drugs may be eligible for financial reimbursement after a multi-state settlement agreements with three pharmaceutical manufacturers.
Advertisements
Pennsylvania joined a coalition of 45 states and territories seeking judicial approval for settlements with Ascend Laboratories, Citron Pharma, and Mayne Pharma.
The legal actions are over claims that the generic drug makers participated in a widespread conspiracy aimed at driving up prices and reducing options for consumers, according to Pennsylvania Attorney General Dave Sunday.
The allegations involve efforts by the firms to manipulate drug pricing, stifle market competition, and impose unlawful trade restrictions across the generic pharmaceuticals sector, according to the attorney general’s office.
Advertisements
As part of the agreements, all three companies agreed to meaningful injunctive provisions, including internal organizational changes to ensure compliance with antitrust laws and support fair competition.
In addition, Ascend will pay $400,000 and Mayne will pay $650,000 to the states.
Advertisements
Consumers who bought generic prescription drugs between May 2009 and December 2019 may qualify for compensation.
Individuals can check eligibility or file a claim by calling toll-free at 1-866-290-0182, emailing info@AGGenericDrugs.com, or visiting www.AGGenericDrugs.com.
“This is the latest action in this national coalition’s fight to hold accountable companies, large and small, who harmed consumers in need of medications that keep them well,” Sunday said. “By limiting market competition while inflating prices, Pennsylvanians had no recourse but to pay unfair prices manipulated by these manufacturers.”
The developments arrive as the coalition prepares for its first trial in the overarching litigation, which is scheduled for February 2027 in Hartford, Connecticut.
Advertisements
The participating states previously reached settlements totaling $496.5 million with other generic drug producers, including Sandoz, Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure.
The litigation comes from a series of investigations supported by input from key cooperating witnesses involved in the alleged schemes.
Advertisements
Investigators relied on a document repository containing more than 20 million items, alongside a phone call database detailing millions of records and contact information for over 600 sales and pricing executives in the generic drug industry, officials said.
The settlement coalition is made up of 45 states and territories, including Alaska, Arizona, California, Colorado, Connecticut, Delaware, the District of Columbia, Florida, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.
